• OUTLOOK ARENA
  • VIEWS ON NEWS
  • OCTOBER 14, 2000

Sectoral funds – Weekly roundup

The markets witnessed one of the most miserable weeks in recent times. The BSE Sensex slumped 8.6% to close at 3,739 points, while the S&P CNX Nifty crashed 8.4% to close at 1,177 points.

Open-ended, IT FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
Pru ICICI Tech. (Gr)5.1-7.1%-22.9%0.0%-48.3%
Alliance New Millenn (Gr)7.5-8.2%-23.2%0.0%-51.1%
Birla IT Fund (Gr)15.6-8.3%-25.5%-15.5%9.5%
K P Internet Opport.(Gr)6.7-8.3%-22.0%0.0%-29.7%
DSP ML Tech.com (Gr)7.1-8.6%-24.6%0.0%-16.4%
K Tech6.3-8.9%-24.4%0.0%-19.4%
K P Infotech (Gr)24.8-9.2%-21.6%21.4%116.4%
IL&FS eCOM Fund (Gr)5.1-9.4%-28.6%0.0%-62.4%
Tata IT Sector Fund9.4-10.0%-28.2%-5.4%16.4%
UTI Sector- Software17.8-10.8%-28.4%9.5%33.3%
Chola Freedom Tech (Reg)8.4-11.2%-22.9%-17.2%10.7%
Magnum Sector Funds-IT13.0-13.5%-28.0%-2.1%81.1%

Excellent results from Infosys (134% year-on-year growth in net profit) and Satyam (118% net profit growth) failed to perk up the markets. On the contrary, markets actually fell after the declaration of results. Other tech companies (NIIT, Global Tele) are expected to declare excellent results. Currently most software stocks are trading at 52-week lows. However, it remains to be seen whether these two factors will spur buying in what is turning out to be a very lacklustre market.

Open-ended, Pharma FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
K P Pharma (Gr)9.5-2.0%-7.3%-39.3%1.4%
Magnum Sector Funds-Pharma9.2-2.5%-9.7%-39.2%-6.8%
UTI Sector-Pharma9.5-3.2%-9.8%-34.1%-19.1%

Ranbaxy and Cipla were the only pharma stocks to see some buying during the week. The mood in pharma stocks is still subdued and there is little buying currently. In the near term, good quarterly results from pharma majors seems to be only trigger that can change this situation.

Open-ended, FMCG FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
K P FMCG (Gr) 11.2-1.4%-10.1%-14.2%9.3%
Pru ICICI FMCG (Gr)9.2-1.7%-9.7%-26.6%-7.6%
Magnum Sector Funds-FMCG8.1-3.6%-14.9%-37.2%-15.0%

With the exception of Nestle and Britannia, fast moving consumer goods (FMCG) stocks witnessed little buying. Poor results by Hindustan Lever (16% year-on-year growth in net profit) is just what the FMCG sector did not need at this time. The outlook for FMCG stocks continues to be negative and buying is still elusive.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407